Colon
- Home
- Cancer Infomation
Etiology & Risk Factors
Colon cancer (CC) arises primarily from the glandular epithelium of the colon.Its pathogenesis is a complex interplay between genetic susceptibility and environmental exposures.
1. Genetic Predispositions
Approximately 20–30% of cases have a familial component, while 5–10% are linked to high-penetrance hereditary syndromes:
- Lynch Syndrome (HNPCC): Germline mutations in DNA mismatch repair (MMR) genes.This is the most common hereditary cause.
- Familial Adenomatous Polyposis (FAP): Caused by mutations in the APC gene, leading to hundreds of polyps and a near 100% lifetime risk of colon cancer if untreated.
- Somatic Mutations: The "adenoma-to-carcinoma sequence" frequently involves APC inactivation, followed by KRAS or BRAF activation and TP53 loss.
2. Environmental & Lifestyle Triggers
- Dietary Factors: High intake of processed and red meats; low dietary fiber, fruit, and vegetable consumption.
- Modifiable Factors: Obesity (central adiposity), sedentary lifestyle, long-term tobacco use, and heavy alcohol consumption.
- Medical History: Chronic inflammatory bowel diseases (IBD), such as Ulcerative Colitis or Crohn's disease, significantly elevate risk due to chronic mucosal inflammation.
Clinical Manifestations (Symptoms)
Symptoms vary depending on the tumor’s location (Right-sided vs. Left-sided) and the stage of progression.
Early-Stage
- Often asymptomatic, highlighting the critical importance of screening (colonoscopy).
- Occult Bleeding: May present only as iron-deficiency anemia (fatigue, pallor), particularly common in right-sided/ascending colon tumors.
- Vague abdominal discomfort or bloating.
Paraneoplastic Syndromes
While less common than in lung or breast cancers, CC can present with:
- Dermatological: Acanthosis nigricans or the Sign of Leser-Trélat (sudden eruptive seborrheic keratoses).
- Hematological: Granulocytosis or thrombophlebitis migrans (Trousseau syndrome).
Advanced-Stage Symptoms
- Hematochezia or Melena: Visible blood in or on the stool.
- Changes in Bowel Habits: Narrowing of stool caliber ("pencil stools"), constipation, or diarrhea—more frequent in left-sided/descending colon tumors.
- Obstructive Symptoms: Colicky abdominal pain, distention, and vomiting.
- Systemic Signs: Significant unintentional weight loss and cachexia.
Diagnostic Workup
The diagnostic pathway focuses on definitive tissue diagnosis and molecular characterization to guide precision medicine.
1. Gold-Standard Diagnosis
- Colonoscopy with Biopsy: The definitive diagnostic tool. It allows for direct visualization and procurement of tissue samples from suspicious lesions.
2. Biomarker Testing (The 2026 Standard)
Pathology reports must now include a comprehensive molecular profile:
- MMR/MSI Status: Assessment of Mismatch Repair deficiency (dMMR) or Microsatellite Instability (MSI-H). This is critical for determining immunotherapy eligibility.
- RAS/BRAF Mutations: Testing for $KRAS$, $NRAS$, and $BRAF$ ($V600E$) mutations is mandatory for metastatic disease to determine resistance to anti-EGFR therapies.
- HER2 Status: Emerging as a vital biomarker for targeted therapy in $RAS$ wild-type patients.
3. Liquid Biopsy (ctDNA)
As of 2026, Circulating Tumor DNA (ctDNA) is increasingly used for:
- Molecular Residual Disease (MRD): Post-surgical monitoring to identify patients at high risk of recurrence who require intensive adjuvant chemotherapy.
Common Investigations & Staging
Imaging Modalities
- CT Chest/Abdomen/Pelvis with IV Contrast: The standard for initial staging to assess local extension, lymphadenopathy, and distant metastases (liver, lungs).
- MRI (Liver/Pelvis): Superior for characterizing indeterminate liver lesions and essential for the local staging of rectal cancer (though less common for proximal colon).
- PET-CT: Not used routinely but valuable for identifying occult metastases or clarifying equivocal findings on CT.
Treatment Overview
1. Surgery
The cornerstone of curative intent for Stage I–III disease.
- Procedures: Radical hemicolectomy (Right, Left, or Extended) with wide field lymphadenectomy (at least 12 nodes).
- Approach: Laparoscopic and Robotic-Assisted surgery are the gold standards, offering faster recovery and equivalent oncologic outcomes compared to open surgery.
2. Radiotherapy
Generally not used for colon cancer (unlike rectal cancer) unless there is palliative need or localized recurrence in the retroperitoneum.
- SBRT (Stereotactic Body Radiation Therapy): Used for oligometastatic disease (e.g., limited liver or lung metastases).
3. Systemic Therapy
- Chemotherapy: FOLFOX (5-FU, Leucovorin, Oxaliplatin) or CAPOX (Capecitabine, Oxaliplatin) remain the standard adjuvant treatments.
- Targeted Therapies: * Anti-VEGF (Bevacizumab): Used in first-line metastatic settings.
- Anti-EGFR (Cetuximab/Panitumumab): Strictly for $RAS/BRAF$ wild-type tumors.
- Immunotherapy: Checkpoint inhibitors like Pembrolizumab or Nivolumab/Ipilimumab are now first-line for dMMR/MSI-H metastatic colon cancer.
2026 Emerging Therapies
- Neoadjuvant Immunotherapy: Following the success of the NICHE-2 trials, using immunotherapy before surgery for dMMR patients is becoming a standard to achieve pathological complete responses.
- KRAS G12C Inhibitors: Drugs like Adagrasib or Sotorasib(in combination with Cetuximab) are providing new hope for patients with the $KRAS$ $G12C$ mutation.
- T-DXd (Trastuzumab Deruxtecan): Showing remarkable efficacy in HER2-amplified metastatic CC.
Medical Disclaimer
This guide is intended for medical professionals and researchers for informational purposes.
It does not replace clinical guidelines or professional medical advice.
Treatment should be determined by a multidisciplinary tumor board.
Please refer to the latest NCCN, ESMO, or ASCO updates for specific clinical decision-making.